MedTrace Logo

Nicotinic Modulation of Schizophrenia-like Information Processing Deficits in Healthy Subjects

NCT00690170 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-05-09

No results posted yet for this study

Summary

This study examines the interactive effects of ketamine and nicotine.

Conditions

  • Healthy Subjects

Interventions

DRUG

Ketamine

Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes

DRUG

Nicotine

Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)

DRUG

Placebo

Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes

DRUG

Ketamine and Nicotine

0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes. 13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)

Sponsors & Collaborators

  • Yale University

    lead OTHER

Principal Investigators

  • Deepak C D'Souza, M.D. · Yale University School of Medicine, Department of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2002-12-31
Primary Completion
2009-06-30
Completion
2009-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690170 on ClinicalTrials.gov